1. Voge, NV, Alvarez, E. Monoclonal antibodies in multiple sclerosis: present and future. Biomedicines 2019; 7: E20.
Google Scholar | Crossref | Medline2. Hauser, SL, Waubant, E, Arnold, DL, et al. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N Engl J Med 2008: 358: 676-88.
Google Scholar | Crossref | Medline3. Hawker, K, O’Connor, P, Freedman, MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66: 460–471.
Google Scholar | Crossref | Medline | ISI4. Hauser, SL, Bar-Or, A, Comi, G, et al. Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med 2017; 376: 221–234.
Google Scholar | Crossref | Medline | ISI5. Kappos, L, Li, D, Calabresi, PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011; 378: 1779–1787.
Google Scholar | Crossref | Medline | ISI6. Dunn, N, Juto, A, Ryner, M, et al. Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies. Mult Scler 2018; 24: 1224–1233.
Google Scholar | SAGE Journals | ISI7. Yamout, BI, El-Ayoubi, NK, Nicolas, J, et al. Safety and efficacy of rituximab in multiple sclerosis: a retrospective observational study. J Immunol Res 2018; 2018: e9084759.
Google Scholar | Crossref | Medline8. Alping, P, Frisell, T, Novakova, L, et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol 2016; 79: 950–958.
Google Scholar | Crossref | Medline | ISI9. Vollmer, BL, Wallach, AI, Corboy, JR, et al. Serious safety events in rituximab-treated multiple sclerosis and related disorders. Ann Clin Transl Neurol 2020; 7: 1477–1487.
Google Scholar | Crossref | Medline10. Mayer, L, Kappos, L, Racke, MK, et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord 2019; 30: 236–243.
Google Scholar | Crossref | Medline11. Montalban, X, Hauser, SL, Kappos, L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017; 376: 209–220.
Google Scholar | Crossref | Medline | ISI12. New Data Further Reinforce Genentech's Ocrevus (ocrelizumab) as a highly effective treatment for people with multiple sclerosis, https://www.businesswire.com/news/home/20200910006081/en/New-Data-Further-Reinforce-Genentech%E2%80%99s-Ocrevus-ocrelizumab-as-a-Highly-Effective-Treatment-for-People-With-Multiple-Sclerosis (2020, accessed 16 December 2020).
Google Scholar13. Genentech: Press Releases | Thursday, Apr 15, 2021, https://www.gene.com/media/press-releases/14905/2021-04-15/new-data-for-genentechs-ocrevus-ocrelizu (accessed 12 July 2021).
Google Scholar14. Granqvist, M, Boremalm, M, Poorghobad, A, et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol 2018; 75: 320–327.
Google Scholar | Crossref | Medline15. National Cancer Institute. National Cancer Institute Updates CTCAE to v.4.0, http://www.oncology.tv/SymptomManagement/NationalCancerInstituteUpdatesCTCAEtov403.aspx (accessed 4 May 2020).
Google Scholar16. Kurtzke, JF . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1444.
Google Scholar | Crossref | Medline | ISI17. Learmonth, YC, Motl, RW, Sandroff, BM, et al. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol 2013; 13: 37.
Google Scholar | Crossref | Medline | ISI18. Hartung, H-P . Ocrelizumab shorter infusion: primary results from the ENSEMBLE PLUS substudy in patients with MS. Neurol Neuroimmunol Neuroinflamm 2020; 7: e807.
Google Scholar | Crossref | Medline19. Vollmer, TL, Cohen, JA, Alvarez, E, et al. Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. Mult Scler Relat Disord 2020; 46: 102454.
Google Scholar | Crossref | Medline20. Moreira Ferreira, VF, Kimbrough, DJ, Stankiewicz, JM. A possible case of serum sickness after ocrelizumab infusion. Mult Scler 2021; 27: 155–158.
Google Scholar | SAGE Journals | ISI21. Wolf, AB, Ryerson, LZ, Pandey, K, et al. Rituximab-induced serum sickness in multiple sclerosis patients. Mult Scler Relat Disord 2019; 36: 101402.
Google Scholar | Crossref | Medline22. Thurlings, RM, Teng, O, Vos, K, et al. Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69: 409–412.
Google Scholar | Crossref | Medline